The TriHealth Hatton Research Institute's Oncology research team, and researchers at TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.
Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials.
Selected trials:
What is a Clinical Trial?
A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.
Clinical trials are important today for many reasons, including:
- Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
- Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure
More Information
For additional basic information about clinical trials:
- Introduction to Cancer Research
- National Cancer Institute’s brochure: “Taking Part in Cancer Treatment Research Studies”
- National Cancer Institute website
- National Institutes of Health website
- National Comprehensive Cancer Network website
- National Cancer Institute video about volunteering for a clinical trial
- The American Cancer Society
Clinical Oncology Trials
| Oncology: Breast |
|---|
|
A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3, N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
D3614C00001: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA1181: (CompassHER2-pCR): Preoperative THP and postoperative de-escalation in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Gastrointestinal |
|---|
|
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma. Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Genitourinary |
|---|
|
A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Gynecology |
|---|
|
GOG-0263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-CC008: A Non-randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1. Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GY020: A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Hematology |
|---|
|
TAK-981-1503: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Lung Cancer |
|---|
|
61186372NSC3002: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| CA209-77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer. Learn More.
Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
MK7902-008: A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Melanoma/Skin |
|---|
|
20130193: A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Molecular Profiling |
|---|
|
EAY131: Molecular Analysis for Therapy Choice (MATCH). Principal Investigator and Contact information: Study Coordinator and Contact information: Diann Fischesser, RN |
|
S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| Oncology: Sarcoma |
|---|
| Oncology: Other |
|---|
| Oncology: Tempus TIME Trials |
|---|
|
TPX-0005-01: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |